- ¥123bn
- ¥159bn
- ¥30bn
Table: Nxera Pharma -2024 group results (IFRS)
Table: Nxera Pharma -2024 parent results
Factbox: Weight-loss drug developers line up to tap market worth $150 billion
Table: Nxera Pharma -9-MTH group results (IFRS)
Brief: Nxera Pharma Says Receives $35 Mln From Neurocrine Biosciences Upon Positive Phase 2 Data For Partnered Schizophrenia Candidate NBI-1117568
Factbox: Weight-loss drug developers line up to tap market worth $150 billion
Brief: Nxera Pharma Receives $10 Mln From Abbvie
Factbox: Weight-loss drug developers hoping to join potential $100 bln market
Table: Nxera Pharma -Q1 group results (IFRS)
Nxera Pharma Notes Successful Development Progress Of Partnered Schizophrenia Candidate Nbi-1117568
Announce Exclusive Supply And Distribution Agreement With Handok For Pivlaz In South Korea
Brief: Nxera Pharma Is The New Name For Sosei Group
Brief: Sosei Group Corp To Develop First-In-Class Treatments Targeting All Symptoms Of Schizophrenia With Boehringer Ingelheim
Factbox: Novo Nordisk brings new contender in race for blockbuster obesity drugs
Factbox: Drugmakers deepen efforts to tap into booming market for obesity drugs
2023 parent results
2023 group results (IFRS)
Factbox: Drugmakers deepen efforts to tap into booming market for obesity drugs
Brief: Sosei Group Corp - Group Announces Marketing Approval For Pivlaz (Clazosentan Sodium) 150 Mg In South Korea